Sanofi said that Sarclisa, its treatment for plasma cell cancer, was recommended for EU approval by the European Medicines Agency. The agency's Committee for Medicinal Products for Human Use ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

The stock currently offers a 4% dividend yield ... We can see from my table above that Sanofi is undervalued by 55% to peers ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab ... 23 abstracts at the American Society of ...

Shares of NASDAQ SNY opened at $50.14 on Wednesday. The stock has a market cap of $127.25 billion, a PE ratio of 25.83, a ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after ... and trying to market this," CEO John Jacobs ...

The neobanking stock has been on a tear in the wake of the election. While it didn’t see nearly the same boost as traditional ...

Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...